Tumor Response Evaluation Transarterial Chemoembolization-treated Hepatocellular Carcinoma | Zendy

Juferdy Kurniawan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tumor Response Evaluation Transarterial Chemoembolization-treated Hepatocellular Carcinoma

Author(s) -

Juferdy Kurniawan

Publication year - 2016

Publication title -

the indonesian journal of gastroenterology hepatology and digestive endoscopy

Language(s) - English

Resource type - Journals

eISSN - 2302-8181

pISSN - 1411-4801

DOI - 10.24871/17120161-2

Subject(s) - hepatocellular carcinoma , medicine , transarterial embolization , radiology , oncology , embolization

Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (HCC), as recommended by Barcelona Clinic Liver Cancer (BCLC) 2016 staging system. Data showed that patients treated with conventional TACE had longer median survival time (18-28,7 months) compared to those who did not (9,2-19,7 months).1 However, the clinicians have to select carefully which of their patients are suitable for undergoing TACE.2

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research